Adding adjuvant pembrolizumab to chemotherapy only led to a benefit in patients with mismatch repair-deficient high-risk endometrial cancers, a phase 3 trial found.
to adjuvant chemotherapy did not improve disease-free survival in the"all-comer" intention-to-treat population. However, in prespecified subgroup analyses, patients with mismatch repair-deficient tumors did demonstrate a significant and clinically meaningful improvement in disease-free survival with immune checkpoint inhibitor therapy.
Patients were randomly allocated to receive adjuvant pembrolizumab or placebo every 3 weeks for six cycles plus, followed by pembrolizumab 400 mg or placebo every 6 weeks for four or six cycles. Radiotherapy was at the investigator's discretion. In contrast, in the dMMR subgroup, 2-year disease-free survival rates were significantly improved in the pembrolizumab group — 92% vs 80% without .
The pembrolizumab group did experience more grade 3 or higher adverse events ,"which is expected when you add an additional treatment," but the safety profile of combination therapy appeared"manageable," Van Gorp noted.
Endometrial Cancer Carcinoma Of The Endometrium Cancer Of The Endometrium Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Biologic Therapy Biologics Gynecological Cancers Chemotherapy Adjuvant Chemotherapy Immunotherapy Tumor Radiation Therapy Radiotherapy Radiation Oncology Surgery Biomarker Biological Marker Multi-Biomarker Disease Activity MBDA
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Targeted cancer cell therapy may slow endometrial cancerThere may be a way to slow the growth of endometrial cancer using targeted cancer cell therapy to silence the ERBB2 gene expression.
Read more »
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical CancerPatients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with standard concurrent chemoradiotherapy.
Read more »
Should All Patients With Early Breast Cancer Receive Adjuvant Radiotherapy?Researchers analyzed data from patients with early breast cancer who were randomized to receive high-dose or no radiotherapy.
Read more »
Endometrial Cancer Test Misses Cases In Black Women, Study ShowsLa’Draya Macon, a New York state social worker, pushed to get a mammogram after discovering a lump during a breast self-exam and was eventually diagnosed with stage 2 breast cancer. Now to mark one year of being breast-cancer free, Macon joins TODAY with her sister La’Dreama and her oncologist Dr.
Read more »
Perioperative Pembrolizumab Continues to Show Benefit in NSCLCThe event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual tumor, suggested analysis.
Read more »
Long-awaited Overall Survival Data Confirm Benefit of Pembrolizumab in TNBCNeoadjuvant plus adjuvant immune therapy combined with chemotherapy reduced death by 34% in the KEYNOTE-522 trial.
Read more »